Regulus Therapeutics Inc. with ticker code (RGLS) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 1.5 and 0.5 with the average target price sitting at 1. Given that the stocks previous close was at 1.3 this would imply there is a potential downside of -23.1%. The 50 day MA is 0.77 while the 200 day moving average is 0.69. The market capitalisation for the company is $90m. You can visit the company’s website by visiting: http://www.regulusrx.com
The potential market cap would be $69m based on the market concensus.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
